Ogo Egbuna works at Vertex leading the company's precision medicine kidney programs in APOL1-mediated and Polycystic kidney disease, which aim to develop potentially curative treatments by targeting the underlying cause of these conditions. Of recent, he worked closely with the KHI board of directors, on the Steering Committee of the KHI project: "Roadmap to Increase Disease Awareness and Clinical Trial Participation of People Carrying High-risk Genetic Variants of APOL1-mediated Nephropathy". He currently serves on the KHI BoD on the biologics subcommittee and the KHI sickle cell nephropathy working group. He completed medical school at the University of Nigeria followed by training in internal medicine at Mount Sinai NY, general nephrology at the University of Rochester, NY, Kidney/Pancreas transplantation medicine at the Beth Israel Deaconess Medical Center in Boston and completed a research fellowship in Endocrinology at the Brigham and Women's Hospital under Dr Edward Brown under an NIH K08 award. He also completed a Masters in Clinical Investigation and therapeutics development under a Pfizer/Merck award at the Harvard/MIT School of Health Sciences and Technology. After training, he worked as an attending transplant physician at Harvard Medical School conducting industry and NIH sponsored research in transplantation before spending a decade at Amgen working on developing biologics for a range of severe diseases and eventually ending up at Vertex.